Verona Pharma plc Verona Pharma To Present At Upcoming Healthcare Investor Conferences

 
TIDMVRP TIDMVRP 
 
 
   LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, today announced that Company management will 
present at three upcoming investor conferences: 
 
   Event: 28th Annual Oppenheimer Healthcare Conference 
 
   Date: March 21, 2018 
 
   Time: 3:55 PM EDT 
 
   Location: New York, NY 
 
   Event: Needham & Co. Annual Healthcare Conference 
 
   Date: March 27, 2018 
 
   Time: 12:15 PM EDT 
 
   Location: New York, NY 
 
   Event: H.C. Wainwright Global Life Sciences Conference 
 
   Date: April 9, 2018 
 
   Time: 2:35 PM CEST 
 
   Location: Monte Carlo, Monaco 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function as compared to 
placebo, and has shown clinically meaningful and statistically 
significant improvements in lung function when administered in addition 
to frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and potentially asthma. 
 
   For further information, please contact: 
 
   Verona Pharma plc 
 
   Jan-Anders Karlsson, Chief Executive Officer 
 
   Tel: +44 (0)20 3283 4200 
 
   info@veronapharma.com 
 
   Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) 
 
   Stewart Wallace / Jonathan Senior / Ben Maddison 
 
   Tel: +44 (0) 20 7710 7600 
 
   SNELVeronaPharma@stifel.com 
 
   FTI Consulting (UK Media and Investor enquiries) 
 
   Simon Conway / Natalie Garland-Collins 
 
   Tel: +44 (0)20 3727 1000 
 
   veronapharma@fticonsulting.com 
 
   ICR, Inc. (US Media and Investor enquiries) 
 
   James Heins 
 
   Tel: +1 203-682-8251 
 
   James.Heins@icrinc.com 
 
   Stephanie Carrington 
 
   Tel. +1 646-277-1282 
 
   Stephanie.Carrington@icrinc.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/

(END) Dow Jones Newswires

March 15, 2018 08:00 ET (12:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024